JF
ADAP

Jump Financial’s Adaptimmune Therapeutics ADAP Stock Holding History

Jump Financial’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-67,665
Closed -$107K – 1754
2024
Q1 		$107K Buy
+67,665
New +$81.7K ﹤0.01% 1783
2022
Q2 		– Sell
-55,600
Closed -$115K – 1564
2022
Q1 		$115K Sell
55,600
-62,800
-53% -$170K ﹤0.01% 1396
2021
Q4 		$444K Buy
+118,400
New +$539K 0.03% 707
2021
Q3 		– Sell
-128,200
Closed -$546K – 1057
2021
Q2 		$546K Buy
+128,200
New +$622K 0.05% 449
2021
Q1 		– Sell
-39,800
Closed -$215K – 897
2020
Q4 		$215K Buy
+39,800
New +$216K 0.04% 746

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Jump Financial's ADAP Position: Q2 2024 in Review

Jump Financial sold out of Adaptimmune Therapeutics (ADAP) in Q2 2024, closing a stake of 67,665 shares — an estimated $107K sold.

Jump Financial first reported a position in ADAP in Q4 2020 and held it in 5 quarters. The position peaked at $546K in Q2 2021. 76 funds tracked by Wall St. Rank hold ADAP as of Q2 2024.

  • Jump Financial reported no remaining Adaptimmune Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Jump Financial sold 67,665 Adaptimmune Therapeutics shares in Q2 2024, an estimated $107K.
  • Jump Financial first reported a position in Adaptimmune Therapeutics in Q4 2020 and held it in 5 quarters.
  • Jump Financial's Adaptimmune Therapeutics position peaked at $546K in Q2 2021.
  • 76 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2024.

Based on Jump Financial's 13F filing for Q2 2024, filed 14 Aug 2024.